Chaney Just (yardflare84)
BACKGROUND Vitamin D status may be an important determinant of health-related quality of life of colorectal cancer (CRC) survivors. The current study investigated longitudinal associations between serum 25-hydroxyvitamin D3 (25OHD3) concentrations and quality of life in stage I-III CRC survivors up to 2 years post-treatment. METHODS CRC patients (n=261) were included upon diagnosis. Home visits (including blood sampling) were performed at diagnosis and at 6 weeks, 6 months, 1 and 2 years post-treatment. Serum 25OHD3 concentrations were measured using liquid chromatography-tandem mass spectrometry and adjusted for season. Validated questionnaires were used to assess global quality of life and cognitive functioning (EORTC-QLQ-C30), fatigue (EORTC-QLQ-C30 and Checklist Individual Strength, CIS), and depression and anxiety (Hospital Anxiety and Depression Scale). Statistical analyses were performed using linear mixed-models and adjusted for sex, age, time since diagnosis, therapy, comorbidities, physical activity, and BMI. RESULTS At diagnosis, 45% of patients were vitamin D deficient ( less then 50 nmol/L). After treatment, 25OHD3 concentrations increased on average with 3.1 nmol/L every 6 months. In confounder-adjusted models, 20 nmol/L increments in 25OHD3 were longitudinally associated with increased global quality of life (β 2.9; 95%CI 1.5,4.3) and reduced fatigue (EORTC-QLQ-C30 subscale β -3.5; 95%CI -5.3,-1.8 and CIS β -2.8; 95%CI -4.7,-0.9). Observed associations were present both within and between individuals over time. CONCLUSIONS Higher concentrations of 25OHD3 were longitudinally associated with better global quality of life and less fatigue in CRC survivors. IMPACT This study suggests that higher 25OHD3 concentrations may be beneficial for CRC survivors. selleck kinase inhibitor Intervention studies are needed to corroborate these findings. Copyright ©2020, American Association for Cancer Research.The outbreak of COVID-19 caused by SARS-CoV-2 virus has now become a pandemic, but there is currently very little understanding of the antigenicity of the virus. We therefore determined the crystal structure of CR3022, a neutralizing antibody previously isolated from a convalescent SARS patient, in complex with the receptor-binding domain (RBD) of the SARS-CoV-2 spike (S) protein to 3.1 Å. CR3022 targets a highly conserved epitope, distal from the receptor-binding site, that enables cross-reactive binding between SARS-CoV-2 and SARS-CoV. Structural modeling further demonstrates that the binding epitope can only be accessed by CR3022 when at least two RBD on the trimeric S protein are in the "up" conformation and slightly rotated. Overall, this study provides molecular insights into antibody recognition of SARS-CoV-2. Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.BACKGROUND AND OBJECTIVES Large, randomized, controlled trials targeting higher hemoglobin level with erythropoiesis-stimulating agents for Western patients with CKD showed harm. However, the effect of anemia correction using erythropoiesis-stimulating agents may differ between CKD subpopulations. The Prevention of ESKD by Darbepoetin Alfa in CKD Patients with Non-diabetic Kidney Disease study, a multicenter, randomized, open-label, parallel-group study, aimed to examine the effect of targeting hemoglobin levels of 11-13 g/dl using darbepoetin alfa with reference to a low-hemoglobin target of 9-11 g/dl on kidney outcome in patients with advanced CKD without diabetes in Japan. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS We enrolled 491 patients with CKD without diabetes, and an eGFR of 8-20 ml/min per 1.73 m2. Of these 491 patients, 239 and 240 were ultimately assigned to the high- and low-hemoglobin groups, respectively (12 patients were excluded). The primary outcome was a kidney composite end point (startTION NUMBER Prevention of ESKD
